Pacira Reports Strong Preliminary Q4 & Full-Year 2025 Revenue Growth, Announces Significant Share Repurchase
Summary
Pacira BioSciences reported preliminary unaudited Q4 and full-year 2025 revenues, highlighted by record-high EXPAREL sales and a substantial $50 million share repurchase, signaling strong operational performance and management confidence.
Key Events
-
Preliminary Full-Year 2025 Revenue Growth
Pacira reported preliminary unaudited total revenue of $726.4 million for the full-year ended December 31, 2025, an increase from $701.0 million in 2024.
-
Record-High EXPAREL Sales in Q4 2025
Preliminary unaudited EXPAREL net product sales reached $155.8 million in Q4 2025, up from $147.7 million in Q4 2024, driven by 7% volume growth and marking the strongest fourth quarter performance in three years.
-
Significant Share Repurchase Program
The company repurchased 2.0 million shares of its common stock for $50.0 million during the fourth quarter of 2025, with $150.0 million remaining on its current authorization.
-
Other Product Sales Performance
Preliminary unaudited Q4 2025 ZILRETTA net product sales were $33.0 million (vs. $33.1 million in 2024), and iovera° net product sales were $7.0 million (vs. $6.5 million in 2024).
Analysis
Pacira BioSciences reported robust preliminary unaudited revenues for Q4 and full-year 2025, driven by record-high EXPAREL sales with 7% volume growth in the fourth quarter. This performance, marking the strongest Q4 in three years for EXPAREL, indicates solid execution on commercial investments and positive momentum for the company's core product. Additionally, the company's repurchase of $50 million in common stock during Q4 demonstrates strong management confidence and a commitment to returning value to shareholders, representing a substantial capital allocation relative to the company's market capitalization. Investors should view these results as a positive indicator of operational strength and financial health.
At the time of this filing, PCRX was trading at $26.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $18.18 to $27.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.